Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Fingolimod 0.5 mg vs interferon beta‐1a

Participants free from MRI gadolinium‐enhancing lesions · patients with relapsing‐remitting multiple sclerosis

Fingolimod 0.5 mg probably leads to higher participants free from MRI gadolinium‐enhancing lesions compared with interferon beta‐1a (moderate certainty).

1 finding from 1 review

Fingolimod for relapsing‐remitting multiple sclerosis 2016 · Cochrane Headline outcomes only
RR 1.12 [1.05, 1.19]
1 study · 728 participants
Moderate

Fingolimod 0.5 mg vs placebo

Participants free from MRI gadolinium‐enhancing lesions · patients with relapsing‐remitting multiple sclerosis

Fingolimod 0.5 mg may leads to higher participants free from MRI gadolinium‐enhancing lesions compared with placebo (low certainty).

1 finding from 1 review

Fingolimod for relapsing‐remitting multiple sclerosis 2016 · Cochrane Headline outcomes only
RR 1.36 [1.27, 1.45]
2 studies · 1226 participants
Low